Log in
NASDAQ:PTGX

Protagonist Therapeutics Stock Forecast, Price & News

$23.85
+0.72 (+3.11 %)
(As of 11/27/2020 12:00 AM ET)
Add
Compare
Today's Range
$23.20
Now: $23.85
$24.96
50-Day Range
$18.49
MA: $21.04
$23.13
52-Week Range
$4.47
Now: $23.85
$24.96
Volume218,400 shs
Average Volume493,289 shs
Market Capitalization$912.43 million
P/E RatioN/A
Dividend YieldN/A
Beta1.54
Protagonist Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops peptide-based product candidates to address unmet medical needs in hematology and gastroenterology. The company is developing PTG-300, an injectable hepcidin mimetic that is in Phase II clinical trial for the treatment of patients with beta-thalassemia by targeting the chronic anemia; PTG-200, an antagonist peptide product candidate, which has completed Phase I clinical trial to treat patients with moderate-to-severe Crohn's disease; and PN-943, an oral, alpha-4-beta-7 specific integrin antagonist that is in Phase I clinical trial for treating inflammatory bowel disease. It is also involved in researching oral and injectable peptide-based product candidates for a range of conditions, including gastrointestinal diseases. The company has a license and collaboration agreement with Janssen Biotech, Inc. for the development, manufacture, and commercialization of PTG-200 for the treatment of Crohn's disease and ulcerative colitis. Protagonist Therapeutics, Inc. was founded in 2006 and is headquartered in Newark, California.
Read More
Protagonist Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.60 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PTGX
CUSIPN/A
Phone510-474-0170
Employees76

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$230,000.00
Book Value$2.94 per share

Profitability

Net Income$-77,190,000.00
Net Margins-438.96%

Miscellaneous

Market Cap$912.43 million
Next Earnings Date3/9/2021 (Estimated)
OptionableNot Optionable
$23.85
+0.72 (+3.11 %)
(As of 11/27/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive PTGX News and Ratings via Email

Sign-up to receive the latest news and ratings for PTGX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Protagonist Therapeutics (NASDAQ:PTGX) Frequently Asked Questions

How has Protagonist Therapeutics' stock price been impacted by COVID-19?

Protagonist Therapeutics' stock was trading at $7.16 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, PTGX shares have increased by 233.1% and is now trading at $23.85.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Protagonist Therapeutics?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Protagonist Therapeutics in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Protagonist Therapeutics
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Protagonist Therapeutics?

Wall Street analysts have given Protagonist Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Protagonist Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Protagonist Therapeutics' next earnings date?

Protagonist Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, March 9th 2021.
View our earnings forecast for Protagonist Therapeutics
.

How were Protagonist Therapeutics' earnings last quarter?

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) issued its quarterly earnings data on Wednesday, November, 4th. The company reported ($0.21) EPS for the quarter, beating the Zacks' consensus estimate of ($0.61) by $0.40. The firm had revenue of $13.11 million for the quarter, compared to analysts' expectations of $3.80 million. Protagonist Therapeutics had a negative net margin of 438.96% and a negative return on equity of 72.42%.
View Protagonist Therapeutics' earnings history
.

What price target have analysts set for PTGX?

5 brokerages have issued twelve-month target prices for Protagonist Therapeutics' stock. Their forecasts range from $27.00 to $33.00. On average, they expect Protagonist Therapeutics' share price to reach $31.20 in the next year. This suggests a possible upside of 30.8% from the stock's current price.
View analysts' price targets for Protagonist Therapeutics
.

Are investors shorting Protagonist Therapeutics?

Protagonist Therapeutics saw a decrease in short interest in the month of October. As of October 15th, there was short interest totaling 2,740,000 shares, a decrease of 16.5% from the September 30th total of 3,280,000 shares. Based on an average daily volume of 348,600 shares, the short-interest ratio is presently 7.9 days.
View Protagonist Therapeutics' Short Interest
.

Who are some of Protagonist Therapeutics' key competitors?

What other stocks do shareholders of Protagonist Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Protagonist Therapeutics investors own include VBI Vaccines (VBIV), Viking Therapeutics (VKTX), ImmunoGen (IMGN), SCYNEXIS (SCYX), Energy Transfer (ET), Strongbridge Biopharma (SBBP), Verastem (VSTM), Dynavax Technologies (DVAX), Novavax (NVAX) and Sorrento Therapeutics (SRNE).

Who are Protagonist Therapeutics' key executives?

Protagonist Therapeutics' management team includes the following people:
  • Dr. Dinesh V. Patel, CEO, Pres, Interim PAO, Sec. & Director (Age 63, Pay $903.41k)
  • Dr. David Y. Liu, Chief Scientific Officer and Head of R&D (Age 70, Pay $654.42k)
  • Dr. Suneel K. Gupta, Chief Devel. Officer (Age 62, Pay $577.8k)
  • Dr. Richard S. Shames, Clinical Advisor (Age 60)
  • Mr. Donald A. Kalkofen, Chief Financial Officer (Age 56)
  • Mr. Matthew M. Gosling, Exec. VP & Gen. Counsel (Age 49)
  • Dr. Samuel R. Saks, Chief Medical Officer (Age 65)
  • Ms. Tracy M. Woody, Exec. VP of Corp. Strategy (Age 50)

When did Protagonist Therapeutics IPO?

(PTGX) raised $70 million in an initial public offering (IPO) on Thursday, August 11th 2016. The company issued 5,800,000 shares at a price of $11.00-$13.00 per share. Leerink Partners, Barclays and BMO Capital Markets served as the underwriters for the IPO.

What is Protagonist Therapeutics' stock symbol?

Protagonist Therapeutics trades on the NASDAQ under the ticker symbol "PTGX."

Who are Protagonist Therapeutics' major shareholders?

Protagonist Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (6.67%), Consonance Capital Management LP (6.19%), State Street Corp (3.02%), JPMorgan Chase & Co. (2.05%), Sofinnova Investments Inc. (0.94%) and Charles Schwab Investment Management Inc. (0.57%). Company insiders that own Protagonist Therapeutics stock include Bryan Giraudo, David Y Liu, Dinesh V Ph D Patel, Donald A Kalkofen, Harold E Selick, Richard S Shames and Suneel Gupta.
View institutional ownership trends for Protagonist Therapeutics
.

Which institutional investors are selling Protagonist Therapeutics stock?

PTGX stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., J. Goldman & Co LP, Arrowstreet Capital Limited Partnership, SG Americas Securities LLC, WINTON GROUP Ltd, Morgan Stanley, Virtus ETF Advisers LLC, and Eqis Capital Management Inc..
View insider buying and selling activity for Protagonist Therapeutics
.

Which institutional investors are buying Protagonist Therapeutics stock?

PTGX stock was acquired by a variety of institutional investors in the last quarter, including Consonance Capital Management LP, State Street Corp, BlackRock Inc., Charles Schwab Investment Management Inc., Sofinnova Investments Inc., California Public Employees Retirement System, AQR Capital Management LLC, and Jane Street Group LLC. Company insiders that have bought Protagonist Therapeutics stock in the last two years include Bryan Giraudo, Donald A Kalkofen, Harold E Selick, and Suneel Gupta.
View insider buying and selling activity for Protagonist Therapeutics
.

How do I buy shares of Protagonist Therapeutics?

Shares of PTGX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Protagonist Therapeutics' stock price today?

One share of PTGX stock can currently be purchased for approximately $23.85.

How big of a company is Protagonist Therapeutics?

Protagonist Therapeutics has a market capitalization of $912.43 million and generates $230,000.00 in revenue each year. The company earns $-77,190,000.00 in net income (profit) each year or ($2.98) on an earnings per share basis. Protagonist Therapeutics employs 76 workers across the globe.

What is Protagonist Therapeutics' official website?

The official website for Protagonist Therapeutics is www.protagonist-inc.com.

How can I contact Protagonist Therapeutics?

Protagonist Therapeutics' mailing address is 7707 GATEWAY BOULEVARD SUITE 140, NEWARK CA, 94560. The company can be reached via phone at 510-474-0170 or via email at [email protected]

This page was last updated on 11/30/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.